In addition to her daily practice as a nurse practitioner at Memorial Sloan Kettering Cancer Center in New York, NY, ONS member Naomi Cazeau, RN, MSN, ANP-BC, AOCNP®, is using her leadership skills to make a difference in advocating for patients on a broader level. In October 2021, the Sepsis Alliance appointed her to its advisory board to help guide the organization’s mission of improving awareness and care.
On November 9, 2021, the U.S. Food and Drug Administration (FDA) reported Aligned Medical Solutions’ recall of its custom convenience kits because of the potential for the plunger of the Cardinal Health monoject flush prefilled syringe (0.9% sodium chloride) to draw back after the air has been expelled and reintroduce air back into the syringe. FDA identified the recall as a class I recall, the most serious type of recall.
Early and regular integration of palliative care (PC) improves patient and caregiver outcomes in symptom management, quality of life, psychosocial health, communication, shared decision-making, overall satisfaction—and even survival. Health systems also benefit through reduced emergency department visits, hospitalizations, and intensive care stays; increased completion of advanced directives; and improved quality of end-of-life care.
Among patients with metastatic, castration-resistant prostate cancer, treatment with the experimental 177Lu-PSMA-617 radiopharmaceutical, along with other standard treatments, improved survival by four months over treatment with standard therapies alone, researchers reported in the New England Journal of Medicine. The therapy targets the PMSA protein and may one day be an option when other treatments have failed.
To confront the disparities that minority populations face in health care, organizations across the United States are recognizing that cultural humility is a clinical competency. Implicit and explicit bias are part of human nature, but prioritizing cultural humility as a foundation, diversifying the workforce, and engaging in education and training can help providers overcome those tendencies and achieve patient-centered care.
During a crisp fall week on September 22–24, 2021, the ONS Board of Directors met in person for the first time since 2019. Dynamics are different when everyone is in the same room, and the Board embraced the energy it infused into its work. Here are some of the important topics they discussed, and ONS members can read the complete minutes from the three-day meeting at ons.org/board-minutes.
Individuals with 10–100+ polyps may have a germline pathogenic variant in the APC gene, placing them at higher risk for developing colorectal, gastrointestinal, and other cancers. The condition is known as familial adenosis polyposis (FAP), and loss of function in the APC gene is the first step in the adenoma-to-carcinoma sequence. Some people have an attenuated form (aFAP), with delayed polyp growth and fewer polyps (see sidebar). As many as 20% are de novo, meaning that they are the first in their family to have an identified pathogenic variant.
A dermatologist-performed total-body skin examination (TBSE) identifies more than two times the number of skin cancers than patients or other providers discovered, researchers reported in the International Journal of Women’s Dermatology. The cancers may otherwise have gone undiagnosed, leading to later-stage disease and poorer outcomes.
Genetic counselors have a unique ability to explain complex genetic information to patients, providers, and our healthcare colleagues and to empower patients to take an active role in their healthcare decisions. We review biosignature data points and help explain the difference between variants that were acquired (somatic) versus those that may have a germline component, or possibly inherited from a parent.
With the growth of genomics and targeted therapy, nurse scientists are gaining deeper understanding the vast facets of patients’ symptom experience, and biosignatures could be the key to unlocking the next frontier in symptom science research.